BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · Endometrial Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerPhase 3 · Recruiting · Extensive-stage Small-cell Lung Cancer
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerPhase 3 · Recruiting · Breast Neoplasms
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerPhase 3 · Recruiting · Metastatic Castration-resistant Prostate Cancer
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIVPhase 1 · Recruiting · HIV -1 Infection
A Study of COVID-19 Vaccine(s) in Children and AdultsPhase 3 · Not Yet Recruiting · COVID-19 Vaccines
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/biontech-se/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.